{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:15:55Z","timestamp":1793675755226,"version":"4.5.1"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    It is well established that estrogens increase the risk of both arterial and venous thrombosis. Abnormally high levels of some coagulation factors combined with a decrease in anticoagulation factors contribute to thrombotic risk. Although estrogens are known to affect multiple hemostatic markers, the exact molecular mechanism of estrogen-induced thrombosis is unclear. However, small changes in these markers with different types, doses, and\/or routes of estrogens may increase thrombotic risk. Most studies on the effect of estrogens have been carried out in premenopausal women using combined oral contraceptives (COCs); studies in postmenopausal women using hormone therapy (HT) are scarce. Short-term studies comparing hemostatic parameters in women receiving either ethinyl estradiol (EE) or estradiol (E\n                    <jats:sub>2<\/jats:sub>\n                    ), each combined with a different progestin, generally show that EE- and E\n                    <jats:sub>2<\/jats:sub>\n                    -based COCs have minimal hemostatic effects on most markers and weaker effects on some markers with E2. The novel estrogen estetrol (E\n                    <jats:sub>4<\/jats:sub>\n                    ), emerging as a promising option for both hormonal contraception and postmenopausal HT, appears to have a neutral hemostatic effect. The increased procoagulant factors and decreased anticoagulatory mechanisms observed with estrogen use have been linked to an increased venous thromboembolism (VTE) risk and have been studied in women using hormonal contraception or HT. In contraceptive studies, it has been shown that estrogen dosage plays a role in VTE risk, as EE increases this risk in a dose-dependent manner. Although some studies suggest that the progestin type in COCs may affect VTE risk, other studies have found no difference in risk between androgenic and non-androgenic progestins. As for the E\n                    <jats:sub>4<\/jats:sub>\n                    -based COC, it is currently being evaluated for VTE risk in post-marketing studies. Regarding postmenopausal HT, both the CEE-alone and CEE\/MPA arms of the Women\u2019s Health Initiative trial showed an increased risk of VTE. However, the results are mixed regarding the impact of oral E\n                    <jats:sub>2<\/jats:sub>\n                    on VTE risk. Although some data suggest a lesser impact of transdermal HT on this risk, further studies are needed to confirm this finding.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2025.1617731","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:13:47Z","timestamp":1758168827000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Chapter 3. Impact of estrogens on hemostasis"],"prefix":"10.3389","volume":"16","author":[{"given":"Frank Z.","family":"Stanczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intira","family":"Sriprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinnisha","family":"Chulapongwanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franca","family":"Fruzzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.beem.2012.11.004","article-title":"History of oral contraceptive drugs and their use worldwide","volume":"27","author":"Christin-Maitre","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1003731","DOI":"10.1371\/journal.pmed.1003731","article-title":"Menopausal hormone therapy and women\u2019s health: An umbrella review","volume":"18","author":"Zhang","year":"2021","journal-title":"PloS Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 Hormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","author":"Faubion","year":"2022","journal-title":"Menopause"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2023.110310","article-title":"Comparison of estrogenic components used for hormonal contraception","volume":"130","author":"Stanczyk","year":"2024","journal-title":"Contraception"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002547","article-title":"Comparison of estrogens and selective estrogen receptor modulators (SERMs) used for menopausal hormone therapy","volume":"32","author":"Stanczyk","year":"2025","journal-title":"Menopause"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102486","article-title":"Estetrol combined to progestogen for menopause or contraception indication is neutral on breast cancer","volume":"13","author":"Gallez","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2009.07.002","article-title":"Basic mechanisms and pathogenesis of venous thrombosis","volume":"23","author":"Esmon","year":"2009","journal-title":"Blood Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.thromres.2010.01.045","article-title":"Mechanisms of estrogen-induced venous thromboembolism","volume":"126","author":"Tchaikovski","year":"2010","journal-title":"Thromb Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/gme.0b013e3181df4a19","article-title":"A review of estrogen receptor alpha gene (ESR1) polymorphisms, mood, and cognition","volume":"17","author":"Sundermann","year":"2010","journal-title":"Menopause"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1042\/CS20160114","article-title":"GPER-novel membrane oestrogen receptor","volume":"130","author":"Zimmerman","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/me.2004-0486","article-title":"Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes","volume":"19","author":"Bj\u00f6rnstr\u00f6m","year":"2005","journal-title":"Mol Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/me.2003-0441","article-title":"Genome-wide identification of high-affinity estrogen response elements in human and mouse","volume":"18","author":"Bourdeau","year":"2004","journal-title":"Mol Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002613","article-title":"Challenges in developing accurate assays for the measurement of estradiol and testosterone in postmenopausal women","author":"Stanczyk","year":"2025","journal-title":"Menopause"},{"key":"B14","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/13697130802056511","article-title":"First human exposure to exogenous single-dose oral estetrol in early postmenopausal women","author":"Visser","year":"2008","journal-title":"Climacteric"},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2165\/00003088-198308020-00001","article-title":"Clinical pharmacokinetics of oral contraceptive steroids","volume":"8","author":"Orme","year":"1983","journal-title":"Clin Pharmacokinet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"18S","DOI":"10.1002\/j.1552-4604.1995.tb04143.x","article-title":"Pharmacokinetic and pharmacologic variation between different estrogen products","volume":"35","author":"O\u2019Connell","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"B17","first-page":"198","article-title":"Steroid-protein interactions II","volume-title":"Monographs on endocrinology","author":"Westphal","year":"1986"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e10418","DOI":"10.1002\/jbm4.10418","article-title":"The free hormone hypothesis: when, why, and how to measure the free hormone levels to assess vitamin D, thyroid, sex hormone, and cortisol status","volume":"5","author":"Bikle","year":"2020","journal-title":"JBMR Plus"},{"key":"B19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1210\/jcem-61-3-499","article-title":"Transport of equine estrogens: binding of conjugated and unconjugated equine estrogens with human serum proteins","volume":"61","author":"Pan","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2012.12.011","article-title":"Ethinyl estradiol and 17\u03b2-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessment","volume":"87","author":"Stanczyk","year":"2013","journal-title":"Contraception"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-40-3-518","article-title":"Circulating estradiol, estrone and gonadotropin levels following the administration of orally active 17beta-estradiol in postmenopausal women","volume":"40","author":"Yen","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(05)80521-1","article-title":"Differences in pharmacokinetics and comparative bioavailability between Premarin\u00ae and Estratab\u00ae in healthy postmenopausal women","volume":"55","author":"Troy","year":"1994","journal-title":"Curr Ther Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(89)90121-6","article-title":"Interindividual variation in the metabolism of ethynylestradiol","volume":"43","author":"Orme","year":"1989","journal-title":"Pharmacol Ther"},{"key":"B24","first-page":"261","article-title":"Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens","volume-title":"Estrogens and antiestrogens II","author":"Kuhnz","year":"1999"},{"key":"B25","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/13697130802073425","article-title":"Estetrol review: profile and potential clinical applications","author":"Coelingh Bennink","year":"2008","journal-title":"Climacteric"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s1071-5576(00)00049-6","article-title":"Comparison of pharmacokinetics of a conjugated equine estrogen preparation (premarin) and a synthetic mixture of estrogens (C.E.S.) in postmenopausal women","volume":"7","author":"Bhavnani","year":"2000","journal-title":"J Soc Gynecol Investig"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(82)90218-6","article-title":"Comparison of pharmacodynamic properties of various estrogen formulations","volume":"144","author":"Mashchak","year":"1982","journal-title":"Am J Obstet Gynecol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-0304","article-title":"Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ER\u03b1 and ER\u03b2","volume":"149","author":"Bhavnani","year":"2008","journal-title":"Endocrinology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3181\/00379727-217-44199","article-title":"Pharmacokinetics and pharmacodynamics of conjugated equine estrogens: chemistry and metabolism","volume":"217","author":"Bhavnani","year":"1998","journal-title":"Proc Soc Exp Biol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.04.005","article-title":"Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins","volume":"74","author":"White","year":"2006","journal-title":"Contraception"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2007.01.027","article-title":"Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen","volume":"75","author":"Sitruk-Ware","year":"2007","journal-title":"Contraception"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0352","article-title":"Effects of oral and transdermal estradiol administration on levels of sex hormone-binding globulin in postmenopausal women with and without a history of intrahepatic cholestasis of pregnancy","volume":"90","author":"Ropponen","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.contraception.2020.08.015","article-title":"Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters","volume":"102","author":"Douxfils","year":"2020","journal-title":"Contraception"},{"key":"B34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.thromres.2020.05.008","article-title":"Estrogen and thrombosis: A bench to bedside review","volume":"192","author":"Abou-Ismail","year":"2020","journal-title":"Thromb Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3109\/13625187.2011.604450","article-title":"Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17\u03b2-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism","volume":"16","author":"\u00c5gren","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0327","article-title":"Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate\/17\u03b2-estradiol, compared with those of levonorgestrel\/ethinyl estradiol. A double-blind, randomised study","volume":"105","author":"Gaussem","year":"2011","journal-title":"Thromb Haemost"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2165\/11590220-000000000-00000","article-title":"Metabolic and haemostatic effects of estradiol valerate\/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study","volume":"31","author":"Junge","year":"2011","journal-title":"Clin Drug Investig"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac511","article-title":"Low thrombin generation in users of a contraceptive containing estetrol and drospirenone","volume":"108","author":"Morimont","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e12612","DOI":"10.1002\/rth2.12612","article-title":"Interlaboratory variability of activated protein C resistance using the ETP-based APC resistance assay","volume":"5","author":"Morimont","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.769187","article-title":"Combined oral contraceptives and venous thromboembolism: review and perspective to mitigate the risk","volume":"12","author":"Morimont","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2020.08.006","article-title":"Letter to the Editors-in-Chief in response to the article of Abou-Ismail, et\u00a0al. entitled \u201cEstrogen and thrombosis: A bench to bedside review\u201d (Thrombosis Research 192 (2020) 40-51)","volume":"193","author":"Morimont","year":"2020","journal-title":"Thromb Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e12684","DOI":"10.1002\/rth2.12684","article-title":"Analytical performance of the endogenous thrombin potential-based activated protein C resistance assay on the automated ST Genesia system","volume":"6","author":"Morimont","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1559162","article-title":"Cost-effective screening strategy to prevent venous thromboembolism in combined oral contraceptive users","volume":"16","author":"Douxfils","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2022.10.014","article-title":"Factor V Leiden-independent activated protein C resistance: Communication from the plasma coagulation inhibitors subcommittee of the International Society on Thrombosis and Haemostasis Scientific and Standardisation Committee","volume":"21","author":"Moore","year":"2023","journal-title":"J Thromb Haemost"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1080\/gye.16.4.335.346","article-title":"The effects of postmenopausal hormone replacement therapy on hemostatic variables: a meta-analysis of 46 studies","volume":"16","author":"Acs","year":"2002","journal-title":"Gynecol Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12560","article-title":"Differential associations of oral estradiol and conjugated equine estrogen with hemostatic biomarkers","volume":"12","author":"Blondon","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000074146.36646.C8","article-title":"Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women","volume":"23","author":"Post","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1067\/s0002-9378(03)00599-4","article-title":"Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study","volume":"189","author":"Post","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0015-0282(01)01829-5","article-title":"Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism","volume":"76","author":"Lobo","year":"2001","journal-title":"Fertil Steril"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.10.013","article-title":"Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis","volume":"120","author":"Eilertsen","year":"2007","journal-title":"Thromb Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12100","article-title":"Biomarkers, menopausal hormone therapy and risk of venous thrombosis: The Women\u2019s Health Initiative","volume":"2","author":"Cushman","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women\u2019s Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1428597","article-title":"Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis","volume":"15","author":"Douxfils","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005509","article-title":"Venous thromboembolic risk of estradiol valerate-dienogest compared with ethinyl estradiol-levonorgestrel combined oral contraceptives","volume":"143","author":"Bauerfeind","year":"2024","journal-title":"Obstet Gynecol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2016.10.005","article-title":"Nonoral combined hormonal contraceptives and thromboembolism: a systematic review","volume":"95","author":"Tepper","year":"2017","journal-title":"Contraception"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010813.pub2","article-title":"Combined oral contraceptives: venous thrombosis","volume":"2014","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B58","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.thromres.2018.03.005","article-title":"Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose","volume":"165","author":"Oedingen","year":"2018","journal-title":"Thromb Res"},{"key":"B59","volume-title":"Assessment Report for Combined Hormonal Contraceptives Containing Medicinal Products-EMA\/739865\/2013","author":"Agency","year":"2014"},{"key":"B60","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/OAJC.S50693","article-title":"Comparison of the pharmacologic and clinical profiles of new combined oral contraceptives containing estradiol","volume":"4","author":"Jensen","year":"2013","journal-title":"Open Access J Contracept"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1080\/13625187.2021.1987410","article-title":"Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17\u03b2-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism","volume":"26","author":"Reed","year":"2021","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3109\/13625187.2013.771860","article-title":"FC3\u201319 Thrombotic diseases in users of estradiol\/dienogest oral contraceptives: a historical national follow-up study 2009 \u2013 2011. Abstracts of Free Communications","volume":"18","author":"Lidegaard","year":"2013","journal-title":"Eur J Contraception Reprod Health Care"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/aogs.14384","article-title":"Systemic hormonal contraception and risk of venous thromboembolism","volume":"101","author":"Heikinheimo","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.17268","article-title":"Use of combined oral contraceptives and risk of venous thromboembolism in young women: a nested case-control analysis using German claims data","volume":"129","author":"Schink","year":"2022","journal-title":"BJOG"},{"key":"B65","unstructured":"Dienogest\/Ethinylestradiol Exeltis (ethinylestradiol, dienogest). SE\/H\/2380\/01\/DC"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2025.2458708","article-title":"Effect over coagulation and fibrinolysis parameters of a prolonged release 24\u2009+\u20094 daily use regime contraceptive formulation containing 2\u2009mg dienogest\/0.02\u2009mg ethinylestradiol","volume":"41","author":"Regidor","year":"2025","journal-title":"Gynecol Endocrinol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91926-0","article-title":"Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","author":"Poulter","year":"1995","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women","volume":"312","author":"Spitzer","year":"1996","journal-title":"BMJ"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.4.817","article-title":"Recurrent use of newer oral contraceptives and the risk of venous thromboembolism","volume":"15","author":"Suissa","year":"2000","journal-title":"Hum Reprod"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(96)07496-x","article-title":"Population-based study of risk of venous thromboembolism associated with various oral contraceptives","volume":"349","author":"Farmer","year":"1997","journal-title":"Lancet"},{"key":"B74","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0010-7824(98)00002-x","article-title":"The risks of venous thromboembolic disease among German women using oral contraceptives: a database study","volume":"57","author":"Farmer","year":"1998","journal-title":"Contraception"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e2990","article-title":"Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10","volume":"344","author":"Lidegaard","year":"2012","journal-title":"BMJ"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3182a5ec6b","article-title":"Cardiovascular risk associated with the use of an etonogestrel-containing vaginal ring","volume":"122","author":"Dinger","year":"2013","journal-title":"Obstet Gynecol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/s0010-7824(01)00307-9","article-title":"Oral contraceptives and venous thromboembolism: a five-year national case-control study","volume":"65","author":"Lidegaard","year":"2002","journal-title":"Contraception"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2921","article-title":"The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study","volume":"339","author":"van Hylckama Vlieg","year":"2009","journal-title":"BMJ"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06780.x","article-title":"Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations","volume":"139","author":"Pomp","year":"2007","journal-title":"Br J Haematol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/ajh.21059","article-title":"Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use","volume":"83","author":"Pomp","year":"2008","journal-title":"Am J Hematol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/s0010-7824(97)00119-4","article-title":"First-time use of newer oral contraceptives and the risk of venous thromboembolism","volume":"56","author":"Suissa","year":"1997","journal-title":"Contraception"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1177\/107602960401000308","article-title":"Effect of age on oral contraceptive-induced venous thrombosis","volume":"10","author":"Girolami","year":"2004","journal-title":"Clin Appl Thromb Hemost"},{"key":"B83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1001\/jamainternmed.2013.11074","article-title":"Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens","volume":"174","author":"Smith","year":"2014","journal-title":"JAMA Intern Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001823","article-title":"Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women Veterans","volume":"28","author":"Blondon","year":"2021","journal-title":"Menopause"},{"key":"B86","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.thromres.2018.06.014","article-title":"Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis","volume":"168","author":"Rovinski","year":"2018","journal-title":"Thromb Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.5114\/pm.2014.46468","article-title":"Menopausal hormone therapy and venous thromboembolism","volume":"13","author":"Bi\u0144kowska","year":"2014","journal-title":"Prz Menopauzalny"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2006.00389.x","article-title":"Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis","volume":"21","author":"Salpeter","year":"2006","journal-title":"J Gen Intern Med"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002229.pub4","article-title":"Hormone therapy for preventing cardiovascular disease in post-menopausal women","volume":"2015","author":"Boardman","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2012.04919.x","article-title":"Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study","volume":"10","author":"Sweetland","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.196022","article-title":"Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study","volume":"30","author":"Canonico","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.17.11.3071","article-title":"Effects of oral and transdermal estrogen\/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial","volume":"17","author":"Scarabin","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615643","article-title":"Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women","volume":"85","author":"Vehkavaara","year":"2001","journal-title":"Thromb Haemost"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14066-4","article-title":"Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e32833c07bc","article-title":"Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women","volume":"17","author":"Oli\u00e9","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1080\/13697137.2019.1703939","article-title":"Association of oral estradiol dose\/levels with coagulation measures in early\/late postmenopausal women","volume":"23","author":"Sriprasert","year":"2020","journal-title":"Climacteric"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1617731\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:13:50Z","timestamp":1758168830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1617731\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":98,"alternative-id":["10.3389\/fendo.2025.1617731"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1617731","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1617731"}}